L-2-hydroxyglutarate production arises from non-canonical enzyme function at acidic pH by Intlekofer, Andrew M. et al.
City University of New York (CUNY) 
CUNY Academic Works 
Publications and Research City College of New York 
2017 
L-2-hydroxyglutarate production arises from non-canonical 
enzyme function at acidic pH 
Andrew M. Intlekofer 
Memorial Sloan Kettering Cancer Center 
Bo Wang 
Memorial Sloan Kettering Cancer Center 
Hui Liu 
Memorial Sloan Kettering Cancer Center 
Hardik Shah 
Memorial Sloan Kettering Cancer Center 
Carlos Carmona-Fontanie 
Memorial Sloan Kettering Cancer Center 
See next page for additional authors 
How does access to this work benefit you? Let us know! 
More information about this work at: https://academicworks.cuny.edu/cc_pubs/511 
Discover additional works at: https://academicworks.cuny.edu 
This work is made publicly available by the City University of New York (CUNY). 
Contact: AcademicWorks@cuny.edu 
Authors 
Andrew M. Intlekofer, Bo Wang, Hui Liu, Hardik Shah, Carlos Carmona-Fontanie, Ariën S. Rustenburg, 
Salah Salah, Marilyn R. Gunner, John D. Chodera, Justin R. Cross, and Craig B. Thompson 
This article is available at CUNY Academic Works: https://academicworks.cuny.edu/cc_pubs/511 
L-2-hydroxyglutarate production arises from non-canonical 
enzyme function at acidic pH
Andrew M. Intlekofer1,2, Bo Wang1, Hui Liu3, Hardik Shah3, Carlos Carmona-Fontaine4, 
Ariën S. Rustenburg4, Salah Salah5, M. R. Gunner5, John D. Chodera4, Justin R. Cross3, 
and Craig B. Thompson1,*
1Cancer Biology & Genetics Program, Memorial Sloan Kettering Cancer Center, NY, 10065, USA
2Department of Medicine, Memorial Sloan Kettering Cancer Center, NY, 10065, USA
3The Donald B. and Catherine C. Marron Cancer Metabolism Center, Memorial Sloan Kettering 
Cancer Center, NY, 10065, USA
4Computational Biology Program, Memorial Sloan Kettering Cancer Center, NY, 10065, USA
5Physics Department, City College of New York, New York, United States, 10031, USA
Abstract
The metabolite 2-hydroxyglutarate (2HG) can be produced as either a D(R)- or L(S)- enantiomer, 
each of which inhibits alpha-ketoglutarate (αKG)-dependent enzymes involved in diverse biologic 
processes. Oncogenic mutations in isocitrate dehydrogenase produce D-2HG, which causes a 
pathologic blockade in cell differentiation. On the other hand, oxygen limitation leads to 
accumulation of L-2HG, which can facilitate physiologic adaptation to hypoxic stress in both 
normal and malignant cells. Here we demonstrate that purified lactate dehydrogenase (LDH) and 
malate dehydrogenase (MDH) catalyze stereospecific production of L-2HG via ‘promiscuous’ 
reduction of the alternative substrate αKG. Acidic pH enhances production of L-2HG by 
promoting a protonated form of αKG that binds to a key residue in the substrate-binding pocket of 
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LDHA. Acid-enhanced production of L-2HG leads to stabilization of hypoxia-inducible factor 1 
alpha (HIF-1α) in normoxia. These findings offer insights into mechanisms whereby 
microenvironmental factors influence production of metabolites that alter cell fate and function.
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The discovery of oncogenic mutations in IDH enzymes demonstrated the profound impact 
that altered metabolism can have on cell identity and function1,2. Mutant IDH enzymes 
efficiently catalyze reduction of αKG to the ‘oncometabolite’ D-2HG3,4. D-2HG inhibits a 
large family of >70 different αKG-dependent enzymes that regulate chromatin-
modifications, stability of hypoxia-inducible factors, extracellular matrix maturation, and 
DNA repair1. In particular, D-2HG-mediated inhibition of chromatin-modifying enzymes 
impairs induction of gene expression programs required for normal cell differentiation and 
‘locks’ malignant cells in an undifferentiated stem cell-like state5–7. The relative 
contributions of different D-2HG targets to oncogenesis likely varies depending on the 
cellular context8,9.
While intensive efforts have been directed at investigating the molecular and cellular effects 
of IDH mutant-derived D-2HG, potential sources and functions of the mirror-image 
enantiomer L-2HG are less well understood10. Importantly, biochemical assays 
demonstrated that L-2HG functions as a more potent inhibitor of αKG-dependent enzymes 
compared to D-2HG; thus cells may be quantitatively more sensitive to changes in L-2HG 
than D-2HG11–13. Indeed, deregulated L-2HG disposal causes significant developmental 
pathology and is associated with brain and kidney cancer14–16.
It was recently reported that hypoxia induces production of L-2HG by both normal and 
malignant cells as a physiologic response to oxygen limitation17,18. Hypoxia-induced 
production of L-2HG occurs independently of HIF but acts to reinforce the hypoxic 
response, at least in part, through stabilization of HIF protein13,17,18. Accumulation of 
L-2HG slows glycolysis and mitochondrial respiration by reducing the regeneration of 
NAD+18. Moreover, hypoxia-induced L-2HG promotes the same repressive chromatin marks 
that characterize the differentiation blockade of IDH-mutant malignancies8,17,19, consistent 
with the well established association between hypoxic niches and stem cell populations20.
Genetic evidence suggests that lactate dehydrogenase and malate dehydrogenase enzymes 
are major sources of hypoxia-induced L-2HG16–18,21, but there has been no demonstration 
that these enzymes directly catalyze L-2HG production. Here we demonstrate that purified 
LDH and MDH enzymes can catalyze stereospecific reduction of αKG to L-2HG and that 
acidic reaction conditions dramatically enhance LDH- and MDH-mediated production of 
L-2HG in vitro and in cells. Mechanistically, acidic pH enhances LDHA-mediated reduction 
of αKG by driving equilibrium toward a protonated form of αKG that binds more stably to 
the LDHA enzyme. In living cells, the pH-dependent induction of L-2HG acts as a potent 
stabilizer of HIF-1α in normoxia, representing a previously unknown pathway of HIF-1α 
stabilization with potential relevance to human disease states. These findings offer new 
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insights in the mechanisms that regulate non-canonical substrate use by metabolic enzymes 
and the consequences of promiscuous L-2HG production in cell physiology.
Results
LDH and MDH enzymes use αKG as an alternative substrate
Hypoxic cells undergo a number of metabolic changes (Fig. 1a) including an increased 
NADH/NAD+ ratio18,22, an increased intracellular concentration of αKG18,23, and 
acidification of the extracellular and intracellular environments24,25. Prior reports implicated 
lactate dehydrogenase A (LDH) and malate dehydrogenase 1 and 2 (MDH) as contributing 
to hypoxia-induced L-2HG in cells (Fig. 1a)17,18. To determine if these enzymes could 
directly produce L-2HG, we tested the ability of purified LDH and MDH to catalyze 
NADH-dependent reduction of their canonical substrates as well as αKG. As expected, 
LDH rapidly consumed NADH in the presence of its canonical substrate pyruvate (Fig. 1b). 
LDH also consumed NADH in the presence of αKG confirming its capacity to utilize 
alternative larger alpha-ketoacid substrates (Fig. 1b)26,27. Likewise, MDH efficiently 
catalyzed reduction of its canonical substrate oxaloacetate (Fig. 1c), while also 
demonstrating an ability to use αKG as a non-canonical substrate, albeit less efficiently (Fig. 
1c).
We performed gas chromatography-mass spectrometry (GC-MS) to determine the identities 
of the alpha-hydroxyacid reaction products generated by LDH and MDH enzymes. Analysis 
of reaction mixtures without enzyme demonstrated that there was no significant non-
enzymatic production of lactate, malate, or 2HG (Fig. 1d–f). LDH, but not MDH, catalyzed 
reduction of pyruvate to lactate (Fig. 1d). Both MDH and LDH catalyzed reduction of 
oxaloacetate to malate, with MDH catalyzing this reaction more efficiently than LDH, as 
expected (Fig. 1e). Notably, both LDH and MDH enzymes were capable of ‘promiscuously’ 
catalyzing NADH-dependent reduction of the alternative substrate αKG to 2HG (Fig. 1f).
LDH and MDH catalyze reduction of αKG to L-2HG
Standard metabolite derivatization and chromatography methods do not distinguish between 
enantiomeric species. In order to separate alpha-hydroxyacid enantiomers, we adapted a 
liquid chromatography-mass spectrometry (LC-MS) protocol involving derivatization of 
metabolites with the chiral compound diacetyl-L-tartaric anhydride (Supplementary Results, 
Supplementary Fig. 1)28. The identity of alpha-hydroxyacid enantiomers was confirmed by 
comparison to similarly derivatized standards (Fig. 2a–c). As expected, chiral derivatization 
showed that LDH catalyzed reduction of pyruvate to L-lactate, whereas MDH catalyzed this 
reaction poorly (Fig. 2a). MDH catalyzed its canonical reaction involving reduction of 
oxaloacetate to L-malate (Fig. 2b), while LDH catalyzed this reaction less effectively (Fig. 
2b). Both LDH and MDH catalyzed stereospecific reduction of αKG to L-2HG (Fig. 2c and 
Supplementary Fig. 2). To ensure that L-2HG production was not facilitated by an unknown 
contaminant of the enzyme preparations (Supplementary Fig. 3a), we also studied 
recombinant human LDHA, MDH1, and MDH2 enzymes. The recombinant enzymes also 
catalyzed stereospecific reduction of αKG to L-2HG (Supplementary Fig. 3b–f). 
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Collectively, these findings substantiate genetic evidence suggesting that LDH and MDH 
enzymes contribute to cellular production of L-2HG16–18,21.
Wildtype IDH and PHGDH enzymes produce D-2HG
Prior reports demonstrated that wildtype isocitrate dehydrogenase enzymes can catalyze 
reduction of αKG to 2HG but the stereochemistry of the 2HG product was not 
determined29,30. Therefore, we sought to assess whether wildtype IDH enzymes might 
represent another cellular source of D- or L-2HG. Using a cell-based assay, we observed that 
transfection with empty vector had no effect on D- or L-2HG levels, whereas transfection 
with wildtype IDH1 or IDH2 selectively increased D-2HG levels (Supplementary Fig. 4a, b 
and 5). Supplementation with cell-permeable αKG substrate resulted in a further increase in 
the amount of D-2HG in cells transfected with wildtype IDH1 or IDH2 (Supplementary Fig. 
4a, b and 5), albeit ~50–100 fold less than that observed in cells transfected with an 
oncogenic IDH1 R132H mutant (Supplementary Fig. 4c).
Commercially available preparations of IDH from porcine heart were impure and thus 
unsuitable for enzymatic assays, prompting us to use recombinant human IDH1 as an 
alternative (Supplementary Fig. 3a). Employing previously reported reaction conditions with 
Tris-based buffers31, we detected substantial non-enzymatic production of 2HG that was 
equally distributed as D- and L- enantiomers (Supplementary Fig. 6). In contrast, non-
enzymatic 2HG production was negligible in phosphate-based reaction buffers 
(Supplementary Fig. 6). Using phosphate-based buffers, we found that recombinant human 
IDH1 selectively catalyzed production of D-2HG (Supplementary Fig. 4d). Taken together, 
the cell-based and recombinant enzyme assays demonstrate that wildtype IDH enzymes can 
catalyze production of D-2HG, an intrinsic enzymatic property that is substantially enhanced 
by the active site arginine residue mutations in IDH observed in cancer29,30.
The enzyme 3-phosphoglycerate dehydrogenase (PHGDH) was recently identified as 
another potential cellular source of D-2HG32,33. Indeed, we found that recombinant human 
PHGDH catalyzed stereospecific reduction of αKG to D-2HG in vitro (Supplemental Fig. 
4e). The locus encoding PHGDH is frequently amplified in breast cancer and 
melanoma34,35, and elevated 2HG levels have been detected in primary breast tumors with 
aggressive features but no IDH mutation36. Thus, determining the chirality of 2HG should 
help elucidate which metabolic pathway contributes to 2HG production in various cancer 
settings.
Acidic pH enhances alternative enzymatic activity of LDH
When investigating the enzymatic properties of LDH, we noted a striking enhancement in 
NADH-dependent reduction of αKG at more acidic pH (Fig. 3a). Specifically, the Km of 
LDH for αKG decreased from >15 mM at pH 7.4 to 3.86 ± 0.97 mM at pH 6.0 (Fig. 3c), a 
value that approximates the concentration of αKG in hypoxic cells18. We found that the 
enhanced rate of αKG-dependent NADH consumption at more acidic pH resulted in 
increased LDH-dependent production of L-2HG (Fig. 3e). Acidification also enhanced the 
ability of MDH to catalyze reduction of αKG to L-2HG, albeit to a lesser degree (Fig. 3b, d, 
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f). Although the rate of non-enzymatic NADH degradation increased at acidic pH, there was 
no detectable non-enzymatic production of L-2HG (Supplementary Fig. 7).
In contrast to the effects on non-canonical substrate usage, acidic pH had no substantial 
effect on the ability of LDH to reduce its canonical substrate pyruvate at a near physiologic 
pyruvate concentration of 0.3 mM (Fig. 3g)37. At concentrations of pyruvate greater than 0.3 
mM, acidic pH impaired the ability of LDH to reduce pyruvate due to enhanced substrate 
inhibition as previously described (Fig. 3g, h)38. Together, these results demonstrate that 
acidification enhances the alternative substrate utilization of lactate dehydrogenase such that 
the non-canonical substrate αKG is relatively favored at lower pH, resulting in increased 
production of L-2HG.
We also examined the effects of acidic pH on the ability of wildtype IDH1 and PHGDH to 
reduce αKG to D-2HG. Wildtype IDH1 exhibited minimal pH-dependent change in D-2HG 
production (Supplementary Fig. 8a). In contrast, PHGDH exhibited enhancement of D-2HG 
production in acidic pH (Supplementary Fig. 8b).
Acidity enhances reduction of a subset of alpha-ketoacids
To determine whether acidic pH might increase accessibility to the substrate-binding pocket 
of LDH, we tested the effect of pH on LDH-mediated reduction of alpha-ketoacids with 
bulky tail groups, including phenylpyruvate (PP) and hydroxyphenylpyruvate (HPP) (Fig. 
4a). We observed that LDH reduced both PP and HPP at a rate at least as great as that of 
αKG, and there were no substantial pH-dependent changes in the rate of reduction for either 
substrate (Fig. 4a). These findings suggest that acidic pH does not function merely to 
enhance access for substrates larger than pyruvate, such as αKG, to the substrate-binding 
pocket of LDH.
We investigated whether the nature of the chemical moiety present in the tail end of the 
alpha-ketoacid substrate might dictate the pH-dependent properties of the LDH enzymatic 
reaction. We identified pairs of alpha-ketoacid substrates of identical carbon-chain length 
that differed only in whether there was a carboxylate or methyl group present in the final 
position (Fig. 4b), including oxaloacetate (OAA; 4-carbon), alpha-ketoglutarate (αKG; 5-
carbon), and oxoadipic acid (OAdA; 6-carbon) along with their respective methylated 
counterparts alpha-ketobutyrate (αKB; 4-carbon), oxopentanoic acid (OPA; 5-carbon), and 
ketohexanoic acid (KHA; 6-carbon). For each substrate pair, only the alpha-ketoacid with a 
carboxylate group in the final position exhibited pH-dependent enhancement of enzymatic 
reduction (Fig. 4b).
Acidification enhances interaction of αKG with LDHA Q100
We performed Monte Carlo protonation state modeling simulations with virtually docked 
substrates to determine whether pH-dependent changes in the protonation states of αKG, 
NADH, or LDHA might be responsible for the acid-enhanced enzymatic reduction of αKG. 
The docked structure of αKG demonstrated that the carboxylate group in the tail of the 
substrate is positioned immediately adjacent to glutamine 100 (Q100) in the substrate-
binding pocket of LDHA (Fig. 5a). Prior reports demonstrated that the corresponding 
residue in bacterial LDH plays an important role in determining substrate specificity39,40.
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Analysis of the Monte Carlo simulations demonstrated a change of the predominant 
protonation state of αKG upon binding LDHA with NADH. The carboxylate tail of αKG 
has a predicted pKa of 4.28 ± 1.27 (closely matching the experimental pKa of 4.4)41, 
indicating that it would be mostly deprotonated in solution at pH values ranging from 6.0 to 
7.4. However, upon binding to LDHA, the carboxylate tail of αKG becomes protonated 
whereupon it is predicted to form a hydrogen bond with Q100 (Fig. 5b). This is associated 
with a free energy penalty for protonating the carboxylate tail that opposes binding, which 
for a given pH can be expressed as
where  is the Boltzmann constant and T equals the absolute temperature. Protonating the 
carboxylate tail at pH 7.4 would cost 3.2 kBT more than protonating it at pH 6.0 (Fig. 5c). 
The expected fold change in the aqueous concentration of the deprotonated form is 
calculated as follows:
If the enzyme greatly prefers to bind the protonated form, then the predicted Km of αKG 
would be approximately 25 times higher (lower affinity) at pH 7.4 than at 6.0, absent 
additional pH-dependent effects. These predictions are consistent with the increased Km 
measured experimentally for αKG at pH 7.4 compared to pH 6.0 (Fig. 3c).
Mutation of Q100 to a positively charged amino acid might alter the substrate preference for 
LDHA, such that it would favor αKG with the carboxylate tail in the deprotonated 
(negatively charged) state, thus abolishing the pH trend observed with the wildtype LDHA 
enzyme. Indeed, mutation of the corresponding residue in bacterial LDH from glutamine to 
arginine (Q102R) enhanced the ability of the enzyme to reduce oxaloacetate39,40. Therefore, 
we generated vectors expressing either wildtype LDHA (LDHA WT) or LDHA with a point 
mutation resulting in replacement of glutamine 100 with arginine (LDHA Q100R). The 
constructs were transfected into 293T cells, and the FLAG-tagged enzymes were purified by 
immunoprecipitation (Supplementary Fig. 9). Equal quantities of enzyme were used for in 
vitro reactions with NADH cofactor and the substrates alpha-ketoglutarate (αKG), 
oxopentanoic acid (OPA), pyruvate (Pyr), and oxaloacetate (OAA; Fig. 5d–g).
In contrast to the acid-enhanced reduction of αKG mediated by wildtype LDHA, the LDHA 
Q100R mutant exhibited a relatively faster rate of αKG reduction at higher pH values with 
no enhancement of activity as the pH decreased (Fig. 5d). Thus the positive charge of the 
Q100R appears to eliminate the energetic penalty normally required to protonate the 
carboxylate tail of αKG. In contrast, the LDHA Q100R mutant exhibited relatively impaired 
enzymatic reduction of oxopentanoic acid, which has a methyl group in the tail position 
(Fig. 5f). Likewise, the LDHA Q100R mutant exhibited a relative preference for 
oxaloacetate (Fig. 5e) and a relatively impaired ability to reduce pyruvate (Fig. 5g). Taken 
together, these findings suggest that acidic pH enhances the ability of wildtype LDHA to 
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reduce substrates with a carboxylate group in the final position by diminishing the energetic 
penalty of protonating the substrate tail to accommodate binding with glutamine 100 in the 
LDHA substrate-binding pocket. The LDHA Q100R mutant introduces a positively charged 
residue at the Q100 site, which alters substrate preference such that alpha-ketoacids with 
carboxylate tails need not pay the energetic cost of being protonated to bind and are 
relatively favored at higher pH values.
Acid-enhanced production of L-2HG stabilizes HIF-1α
Given the striking enhancement of LDH-catalyzed L-2HG production observed in vitro, we 
sought to determine the effects of acidification on 2HG production in cells. Cells grown in 
normoxic conditions were lysed in non-denaturing buffer with pH ranging from 7.5 to 6.0 
(Fig. 6a). Cell lysates were used as a source of enzyme for in vitro reactions with addition of 
αKG and NADH, and 2HG production was assessed by GC-MS. As the reaction pH was 
lowered, there was a progressive increase in the amount of 2HG produced, such that there 
was >3 fold more 2HG at pH 6.0 compared to pH 7.5 (Fig. 6a). Assessment of chirality by 
LC-MS confirmed that acidification of cell lysate reactions potently induced production of 
L-2HG (Fig. 6b). Acid-enhanced L-2HG production was blocked by addition of oxamate, a 
lactate dehydrogenase inhibitor that is a structural analog of pyruvate (Fig. 6b)42. Thus, acid-
enhanced production of L-2HG depends, at least in part, on the enzymatic activity of LDH.
Hypoxia results in acidification of the cellular environment and an increase in the 
intracellular concentration of αKG (Fig. 1a)18,23–25, but it is unclear to what extent these 
conditions might be sufficient to induce production of L-2HG. Therefore, we tested the 
effects of acidified medium and/or exogenous αKG on cells cultured in normoxia (Fig. 6c). 
As previously reported, addition of cell-permeable αKG resulted in a modest increase in 
2HG production in cells cultured in standard medium in normoxia (Fig. 6c)17. However, we 
observed a synergistic enhancement of 2HG production when cells were cultured in 
acidified medium supplemented with cell-permeable αKG (Fig. 6c). Quantification of the 
intracellular concentrations of L- and D-2HG demonstrated that L-2HG levels exceeded 0.3 
mM in acidified media supplemented with cell-permeable αKG (Fig. 6d), approximating 
previous measurements in hypoxic cells17,18. In contrast, D-2HG concentrations were 
approximately 10 fold lower (Fig. 6d). Measurement of intracellular pH with fluorescent 
probes demonstrated a value of pH 6.53 ± 0.29 for cells cultured in acidic medium plus 
αKG (Supplementary Fig. 10).
Cells cultured in acidic medium plus αKG demonstrated a striking stabilization of HIF-1α 
despite the presence of atmospheric oxygen levels (Fig. 6c and Supplementary Fig. 11). The 
observed stabilization of HIF-1α by αKG was paradoxical given the fact that αKG 
functions as substrate for the EGLN enzymes that hydroxylate proline residues on HIF and 
target it for proteasomal degradation43. Therefore, we examined the effects of acidification 
plus αKG on the ratio of hydroxyl-HIF-1α to total HIF-1α in cells cultured in the presence 
of the proteasome inhibitor MG132 (Fig. 6e and Supplementary Fig. 11)44. Cells cultured in 
standard medium plus MG132 accumulated hydroxyl-HIF-1α relative to total HIF-1α in 
response to cell-permeable αKG (Fig. 6e and Supplementary Fig. 11). In contrast, cells 
cultured in acidified medium plus MG132 did not accumulate hydroxyl-HIF-1α despite a 
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substantial increase in total HIF-1α protein (Fig. 6e and Supplementary Fig. 11). Thus, we 
conclude that acid-enhanced L-2HG production stabilizes HIF-1α by inhibiting the αKG-
dependent prolyl hydroxylases that target HIF-1α for degradation, in agreement with 
previously observed effects of L-2HG on prolyl hydroxylases in vitro11,13.
To further explore the possibility that acid-enhanced L-2HG lies upstream of HIF-1α, we 
tested the effects of ablating LDHA and MDH2, the two enzymes primarily responsible for 
L-2HG production in cells17,18. Cells treated with non-targeting control siRNA exhibited 
normoxic stabilization of HIF-1α when cultured in acidic medium supplemented with αKG 
(Fig. 6f and Supplementary Fig. 11). Ablation of either LDHA or MDH2 alone partially 
impaired stabilization of HIF-1α in response to acidification (Supplementary Fig. 12a, b and 
13). However, combined targeting of both LDHA and MDH2 abrogated L-2HG production 
(Supplementary Fig. 12c) and abolished the ability of cells to stabilize HIF-1α in response 
to acidification (Fig. 6f and Supplementary Fig. 11). These findings demonstrate that acid-
enhanced conversion of αKG to L-2HG by LDHA and MDH2 is sufficient to stabilize 
HIF-1α in the absence of hypoxia.
Discussion
Herein we demonstrate that lactate dehydrogenase and malate dehydrogenase enzymes 
catalyze ‘promiscuous’ enzymatic reduction of the alternative substrate αKG to L-2HG. 
Decades-old studies demonstrated alternative substrate use by dehydrogenase enzymes but 
lacked techniques to accurately assess the identity and chirality of metabolite products26,27. 
Our findings indicate that there are multiple enzymes that can reduce αKG to 2HG and that 
the chirality of 2HG is dictated by the specific enzyme involved. For example, LDH and 
MDH enzymes catalyze stereospecific production of L-2HG, whereas wildtype (and mutant) 
IDH and PHGDH catalyze stereospecific production of D-2HG.
The findings presented here substantiate prior genetic evidence implicating LDH and MDH 
as cellular sources of L-2HG16–18,21. In hypoxia, cells selectively produce L-2HG in a 
manner primarily dependent on LDHA and MDH217,18. The relative contributions of LDHA 
and MDH2 to hypoxia-induced L-2HG appear to vary depending on the type of cell, which 
may be related to enzyme levels and subcellular pools of substrate. Hypoxic cells undergo a 
variety of metabolic changes that might favor L-2HG production18,22–25,45. Here we identify 
acidification and increased αKG concentration as factors that are sufficient to induce cellular 
production of L-2HG in normoxia. Indeed, in vitro enzymatic assays demonstrate that the 
promiscuous enzymatic activity of LDH, and to a lesser extent MDH, is enhanced by acidic 
pH, resulting in more efficient reduction of αKG to L-2HG. Acidic pH appears to enhance 
LDHA-mediated reduction of αKG by driving equilibrium toward the protonated state of the 
carboxylate tail, which permits docking of αKG via interaction with the glutamine 100 in 
LDHA. Intracellular acidification might also explain, at least in part, the increased L-2HG 
observed in cells with electron transport chain dysfunction46.
In hypoxia, L-2HG can function as a metabolic signaling molecule that mediates physiologic 
responses to help cells adapt to oxygen limitation17,18. L-2HG acts to stabilize hypoxia-
inducible factors by inhibiting the αKG-dependent prolyl hydroxylases that target HIF for 
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degradation11,13. Whether HIF-1α stabilization is a qualitatively or quantitatively unique 
property of L-2HG compared to D-2HG remains controversial13,47,48. We have identified 
acidosis as previously unappreciated physiologic stimulus that enhances conversion of αKG 
to L-2HG, resulting in robust stabilization of HIF-1α in normoxia. HIF-1α facilitates 
cellular adaptation to an acid load by inducing expression of carbonic anhydrases49, and our 
findings suggest that acid-enhanced L-2HG may be part of this signaling axis. Indeed, we 
find that ablation of LDHA and MDH2 abrogates the ability of acidotic cells to stabilize 
HIF-1α. It is also possible that acidification and L-2HG cooperate in the stabilization of 
HIF-1α50. Compared to L-2HG, we observed approximately 10 fold lower intracellular 
concentrations of D-2HG. Given that L-2HG functions as a more potent inhibitor of αKG-
dependent enzymes than D-2HG11–13, we conclude that D-2HG derived from wildtype IDH 
and/or PHGDH is negligible and likely does not play a physiologic role in this setting.
Promiscuous enzymatic activity results in the production of numerous metabolites that have 
been described as ‘metabolite damage’ or mistakes10. However, emerging evidence suggests 
that L-2HG, a metabolite produced by promiscuous enzyme activity, might represent a 
conserved metabolic response to multiple environmental stimuli including hypoxia and 
acidosis. L-2HG appears to mediate its effects through both HIF-dependent and HIF-
independent mechanisms17,18. Future investigations will be directed at elucidating the 
mechanisms whereby L-2HG regulates physiologic responses to hypoxia and acidosis, as 
well as how deregulation of L-2HG metabolism might contribute to oncogenesis14,15.
Online Methods
Reagents
Purified enzymes were purchased from Sigma, including LDH from bovine heart (L2625), 
LDH from rabbit muscle (L2500), and MDH from porcine heart (M1567). Recombinant 
human enzymes were purchased from Abcam, including LDHA (ab93699), MDH1 
(ab99244), MDH2 (ab99238), IDH1 (ab113858), and PHGDH (ab198455). Substrates, 
cofactors, and inhibitors were purchased from Sigma, including pyruvate, oxaloacetate, 
alpha-ketoglutarate, dimethyl-alpha-ketoglutarate, L-lactate, D-lactate, L-malate, D-malate, 
L-2-hydroxyglutarate, D-2-hydroxyglutarate, alpha-ketobutyrate, oxopentanoic acid, 
oxoadipic acid, ketohexanoic acid, phenylpyruvate, hydroxyphenylpyruvate, NADH, 
NADPH, and oxamate. FLAG-tagged wildtype and Q100R mutant LDHA constructs were 
cloned into the PCDNA3.1(+) vector (Addgene) by standard site-directed mutagenesis and 
verified by Sanger sequencing.
Cell Culture
Adherent cell lines 293T (purchased from ATCC) and SFXL (SF188 cells with stable 
expression of Bcl-XL; generated as previously described51) were maintained at low passage 
number in high glucose DMEM with 10% FBS, glucose 25 mM, glutamine 4 mM, penicillin 
100 units/ml, and streptomycin 100 μg/ml and split every 2–3 days before reaching 
confluence. Cell lines were authenticated by Short Tandem Repeat (STR) profiling. Cell 
lines repeatedly tested negative for mycoplasma throughout the experimental period. For 
siRNA experiments, cells were reverse-transfected with siRNA mixed with Lipofectamine 
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RNAiMAX (Life Technologies) in Opti-MEM Reduced Serum Medium (Life Technologies) 
as described by the manufacturer. The following siRNAs (ThermoFisher) were used: 
siLDHA = J-008201-06, target sequence: GGCAAAGACUAUAAUGUAA; siMDH2 = 
J-008439-12, target sequence: CGCCUGACCCUCUAUGAUA. For experiments with 
acidified medium, standard DMEM was titrated to pH 6.0 at room temperature and 
atmospheric oxygen then filtered through a sterile 0.2 μm filter prior to use in tissue culture.
Western Blotting
Cell lysates were extracted in 1× RIPA buffer (Cell Signaling), sonicated, centrifuged at 
21,000 g at 4° C, and supernatants were collected. Nuclear extracts were prepared by 
harvesting cells in NaCl 50 mM, sucrose 0.5 M, Triton × 0.5% plus protease/phosphatase 
inhibitor cocktail (ThermoFisher). Isolated nuclei were washed with KCl 10 mM then lysed 
in NaCl 500 mM and NP-40 0.1%. Cleared cell lysates or nuclear extracts were quantified 
by BCA assay (ThermoFisher) and normalized for total protein concentration. Samples were 
separated by SDS-PAGE, transferred to nitrocellulose membranes (Life Technologies), 
blocked in 5% milk prepared in Tris buffered saline with 0.1% Tween 20 (TBST), incubated 
with primary antibodies overnight at 4° C then horseradish peroxidase (HRP)-conjugated 
secondary antibodies (GE Healthcare; anti-mouse, NA931V, sheep, 1:5000; anti-rabbit, 
NA934V, donkey, 1:5000) for 1 hr the following day. After incubation with ECL 
(ThermoFisher or GE Healthcare), imaging was performed using the Amersham Imager 600 
(GE Healthcare). Primary antibodies used included: anti-Ezh2 (Cell Signaling, 5246P; 
rabbit; 1:1000), anti-HIF-1α (BD Biosciences, 610959; mouse; 1:200), anti-hydroxyl-
HIF-1α (Cell Signaling, 3434P; rabbit; 1:1000), anti-IDH1 (Proteintech, 12332-1-AP; 
rabbit; 1:1000), anti-IDH2 (Abcam, ab55271; mouse; 1:1000) anti-LDHA (Cell Signaling, 
2012S; rabbit; 1:1000), anti-MDH2 (Abcam, ab96193; rabbit; 1:1000), anti-alpha-tubulin 
(Sigma, T9026: mouse; 1:5000), and anti-vinculin (Abcam, ab18058; mouse; 1:1000).
Intracellular pH Measurement
Cells were loaded with either 5-(and-6)-Carboxy, Acetoxymethyl Ester, Acetate (SNARF-1; 
Thermo) or 2′,7′-Bis-(2-Carboxyethyl)-5-(and-6)-Carboxyfluorescein, Acetoxymethyl Ester 
(BCECF; Thermo) ratiometric pH probes according to the manufacturer’s instructions. After 
loading with pH probe, cells were incubated in DMEM without phenol red that was either 
left unmanipulated or titrated to pH 6.0 with addition of either DMSO (vehicle) or dimethyl-
αKG 5 mM. After 4 hours of incubation at 37° C with 5% CO2, fluorescence was measured 
using a plate reader (Tecan, Infinite M1000). The SNARF-1 probe was detected with a 
single excitation at 514 nm and a dual-emission ratio (580 nm and 640 nm). The BCECF 
probe was detected with a dual-excitation (490 nm and 440 nm) and a fixed emission 
wavelength of 535 nm. Background fluorescence (cells without probes) was subtracted 
before all calculations. Intracellular pH was quantified by a standard curve ranging from pH 
5.5 to pH 7.5 using DMEM with nigericin 10 μM and valinomycin 10 μM to equilibrate 
intracellular pH with extracellular pH.
Enzyme Assays
Enzyme reactions were conducted in potassium phosphate buffer 33 mM titrated to pH 7.4, 
7.0, 6.6, or 6.0. Purified enzymes were used at 5 units/ml, 1 μg/ml, or 10 μg/ml as indicated, 
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and recombinant enzymes were used at 15 μg/ml unless otherwise indicated. FLAG-tagged 
wildtype and Q100R mutant LDHA enzymes were purified from transfected 293T cells 
using Anti-FLAG M2 Affinity Gel (Sigma) according to the manufacturer’s instructions. 
FLAG-tagged enzymes were quantified by BCA assay and gel electrophoresis with 
Coomassie staining. NADH and NAPDH were used at 0.22 mM or 0.30 mM respectively 
throughout unless otherwise indicated. Substrates were used at 1 mM unless otherwise 
indicated. For NADH consumption assays, reactions were conducted in UV-transparent 96-
well plates (Corning) with reaction volumes of 200 μl. A SpectraMax Plus 384 Microplate 
Reader (Molecular Devices) was used to monitor the absorbance at 340 nm every 30 seconds 
or 12 seconds throughout the course of the reaction. For each condition, the mean rate of 
NADH consumption for triplicate control reactions without enzyme was subtracted from the 
rate of NADH consumption for triplicate experimental reactions with enzyme. Reaction 
velocities were calculated using an extinction coefficient for NADH at ε340 of 6220 M−1 
cm−1 and pathlength of 0.56 cm for a 200 μl reaction volume in a standard 96-well plate. For 
NADH consumption assays with purified LDH and pyruvate, reactions were conducted in 
UV-transparent 3-ml cuvettes (BrandTech; pathlength 1 cm) with measurement of the 
absorbance at 340 nm every 2 seconds. For cell lysate enzyme assays, SFXL cells were 
cultured in normoxic conditions in regular DMEM medium and harvested at subconfluence. 
The harvested cells were divided into 4 equal fractions, and non-denaturing cell lysates were 
prepared with PBS plus 0.1% Triton X titrated to pH 7.5, 7.0, 6.5, or 6.0 and used at either 
50 or 100 μl per 200 μl reaction with αKG and NADH. The reaction mixtures were stopped 
after 16 hr, at which time metabolites were extracted, derivatized and analyzed by GC- or 
LC-MS.
Metabolite Extraction and Analysis
Metabolites were extracted with ice-cold 80:20 methanol:water containing 2 μM deuterated 
2-hydroxyglutarate (D-2-hydroxyglutaric-2,3,3,4,4-d5 acid; deuterated-2HG) as an internal 
standard. After overnight incubation at −80° C, cell extract was harvested, sonicated, and 
centrifuged at 21,000 g for 20 min at 4° C to precipitate protein. Extracts were then dried in 
an evaporator (Genevac EZ-2 Elite). For GC-MS, metabolites were resuspended by addition 
of 50 μl of methoxyamine hydrochloride (40 mg/ml in pyridine) and incubated at 30° C for 
90 min with agitation. Metabolites were further derivatized by addition of 80 μl of MSTFA 
+ 1% TCMS (Thermo Scientific) and 70 μl of ethyl acetate (Sigma) and incubated at 37° C 
for 30 min. Samples were diluted 1:2 with 200 μl of ethyl acetate, then analyzed using an 
Agilent 7890A GC coupled to Agilent 5975C mass selective detector. The GC was operated 
in splitless mode with constant helium carrier gas flow of 1 ml/min and with a HP-5MS 
column (Agilent Technologies). The injection volume was 1 μl and the GC oven temperature 
was ramped from 60° C to 290° C over 25 min. Peaks representing compounds of interest 
were extracted and integrated using MassHunter software (Agilent Technologies) and then 
normalized to both the internal standard (deuterated-2HG) peak area and protein content as 
applicable. Ions used for quantification of metabolite levels were 2HG m/z 247 
(confirmatory ion m/z 349), deuterated-2HG m/z 252 (confirmatory ion m/z 354), malate 
m/z 335 (confirmatory ions m/z 233, 245), and lactate m/z 190 (confirmatory ion m/z 219). 
Peaks were manually inspected and verified relative to known spectra for each metabolite.
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For LC-MS, dried samples were derivatized with 100 μl of freshly prepared 50 mg/ml (+)-
diacetyl-L-tartaric anhydride (DATAN, Sigma) in dichloromethane-acetic acid (v/v=4:1) at 
75° C for 30 min. After cooling to room temperature, derivatized samples were dried under 
nitrogen at room temperature and resuspended in 200 μl of UltraPure water (18.2 MΩ, 
PureLab) prior to LC-MS/MS analysis. Analysis was performed on a Thermo Vantage triple-
quadrupole mass spectrometer operating in SRM and negative ionization modes. LC 
separation was using an Acquity UPLC HSS T3 analytical column (2.1×100 mm, 1.8 μm, 
Waters) with an Agilent 1260 infinity binary pump. Mobile phase A was 125 mg/l 
ammonium formate in water adjusted to pH 3.5 with formic acid, mobile phase B was 
methanol, and flow rate was 0.3 ml/min. Initial conditions were 3% B for 5 min, then 
increased to 80% B at 5.5 min and held for a further 2.5 min. 10 min of re-equilibration time 
was used to ensure retention time stability. The column temperature was held at 40° C. 
Samples were kept at 4° C and the injection volume was 5 μl. MS source parameters were 
spray voltage: 2500 V; capillary temperature: 300° C; vaporizer temperature: 250° C; sheath 
gas pressure: 50 psi; aux gas pressure: 40 psi. Compound specific S-lens values were: 37 V 
(2HG), 36 V (malate), 34 V (lactate), 40 V (α-ketoglutarate), and 41 V (deuterated-2HG). 
Individual reactions monitored and collision energies (CE) were: 2HG m/z 363.0 → 147.1 
(CE: 12 V)*, 129.1 (CE: 27 V); malate m/z 349.0 → 133.0 (CE 14 V)*, 115.0 (CE 28 V); 
lactate m/z 305.0 → 89.1 (CE 14 V)*, α-ketoglutarate m/z 145.1 → 57.0 (CE 12 V); 113.0 
(CE 16V); deuterated-2HG m/z 368.0 → 152.1 (CE 13 V)*, 132.9 (CE 22 V), with * 
indicating the primary transition used to quantify each metabolite. Pure standards of L-2HG, 
D-2HG, L-malate, D-malate, L-lactate, and D-lactate were derivatized and analyzed in 
parallel for each chiral determination experiment. The identities of metabolite enantiomers 
were determined by comparing to the retention times of the derivatized pure standards and 
additionally confirmed by spike-ins of derivatized pure standards into the experimental 
sample. Absolute metabolite quantitation was performed using an external calibration curve 
with deuterated-2HG internal standard and the resulting concentrations corrected for the 
total cell volume extracted. Chromatograms were acquired and processed with XCalibur and 
TraceFinder software (ThermoFisher).
Aqueous solution pKa prediction
The aqueous solution  values for the tail carboxylate moiety of αKG were predicted 
using Epik (Schrödinger Release 2015-3)52 using default settings.
Virtual docking of αKG to LDHA
Virtual docking of αKG was performed using Glide XP (Schrödinger release 2015-3)53,54 to 
chain A of the 2.1 Å structure of lactate dehydrogenase A (LDHA pdb identifier: 4OKN55). 
Missing side chains were automatically constructed, amino acids were assigned protonation 
states compatible with a pH of 7.0 using the protein preparation wizard (Schrödinger release 
2015-3), and crystallographic waters were removed. Bond orders for NADH were manually 
verified to avoid misassignment. Oxalate was used as a reference ligand to define the 
binding site, after adding fictitious atoms to ensure minimum atom requirement for binding 
site definition was met. Hydroxyl and thiol groups were allowed to rotate during grid 
generation. The tail-protonated form of αKG was docked in the presence of crystallographic 
NADH. Docking poses were minimized post-docking. The resulting conformations were 
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clustered within a 0.5 Å RMSD cutoff. This resulted in a single representative pose. All 
steps utilized default parameters unless otherwise noted. Poses and predicted hydrogen 
bonds were visualized using PyMOL.
Monte Carlo protonation state modeling using MCCE2 simulations
MCCE256 was used to perform Monte Carlo simulations of amino acid side chain position 
and side chain and substrate protonation at equilibrium. The 2.3 Å structure of lactate 
dehydrogenase A (LDHA pdb identifier: 1I1057) was used as input for all calculations (~60 
computational hours at two Intel® Xeon™ 2.40 GHz Six Core CPU). αKG was modeled 
using a virtually docked pose from previous work17. This structure was prepared using the 
same docking procedure as detailed in this paper. The protonation states were compared 
between structures with the coenzyme and substrate (NADH and αKG) bound to LDHA or 
removed. The same starting protein structure was used for both bound and unbound types of 
simulation. The simulations were performed between pH 4.0–10.0 at intervals of 1.0 pH 
unit, and at pH 6.6 and 7.4. The total number of MC steps for the equilibration at each pH 
was 480000. MCCE2 explores all side chain rotamers. DelPhi58 was used to solve the 
Poisson Boltzmann equation to obtain the pairwise interactions between charged and/or 
polar groups and the solvation energy with an internal dielectric constant of 4.0 and 80 for 
the solvent, with 0.15 salt concentration. The atomic partial charges and radii for the amino 
acids were obtained from PARSE59, while those of the ligands were generated by 
QUACPAC (Openeye toolkit 2016-Jun.1). MCCE2 calculates how the protein modifies the 
solution pKa (pKa,sol) of amino acids and substrates upon transfer into its position in the 
protein. NADH, and αKG protonation states and tautomers, including their relative 
populations were generated and performed using Epik (Schrödinger Release 2015-3). 
Relative Epik energies were calculated at pH 4.0–10.0 at intervals of 1.0 pH unit, pH 6.6 and 
pH 7.4. The energetic description for amino acids or standard ligands includes the pKa,sol as 
well as AMBER60 torsion energies and van der Waals self-interactions. For the substrate, 
values were set to zero and the relative Epik energy of each tautomer and protonation state 
provided the starting reference state in solution. MCCE2 then calculated the shift in relative 
energy within the protein and thus showed the change in their distribution. The protein side 
chain rotamers and protonation states were sampled along with the ligand tautomers and 
protonation states at the given pH.
Data availability
The docking and MCCE2 calculation data, including scripts, have been deposited in 
“figshare” (https://dx.doi.org/10.6084/m9.figshare.4289894.v3). Inside the zip file, see the 
‘Docking’ folder for files used in the docking procedures. Docking was performed using 
Maestro as part of Schrodinger release 2015-3. See the ‘MCCE’ folder for files used for the 
MCCE2 calculations for lactate dehydrogenase A. MCCE calculations were performed 
using MCCE2 (https://sites.google.com/site/mccewiki/install-mcce). Epik calculations were 
performed using Schrodinger release 2015-3.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. LDH and MDH enzymes catalyze reduction of the alternative substrate αKG
(a) Schematic of metabolic changes that occur in hypoxic cells. LDHA, MDH1, and MDH2 
represent potential enzymatic sources of L-2HG production in cells. (b) Enzyme assay 
measuring NADH consumption by LDH purified from bovine heart (5 units/ml) in reactions 
with either no substrate (grey), pyruvate 0.3 mM (green), or αKG 1 mM (blue). (c) NADH 
consumption by MDH purified from porcine heart (5 units/ml) in reactions with either no 
substrate (grey), OAA 0.3 mM (orange), or αKG 3 mM (blue). Data in b and c are mean 
± 95% c.i. for triplicate reactions. (d–f) Alpha-hydroxyacid product formation catalyzed by 
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dehydrogenases. GC-MS analysis of (d) lactate production from pyruvate, (e) malate 
production from oxaloacetate, or (f) 2HG production from αKG in 6 hr enzyme reactions 
with either no enzyme, LDH purified from bovine heart (10 μg/ml), or MDH purified from 
porcine heart (10 μg/ml). Reactions were conducted in potassium phosphate buffer 33 mM, 
pH 7.0, with NADH 0.22 mM. Results throughout figure are representative of ≥3 
independent experiments.
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Figure 2. LDH and MDH selectively produce L-alpha-hydroxyacids, including L-2HG
(a–c) Chiral LC-MS analysis resolving enantiomers of (a) lactate produced from pyruvate, 
(b) malate produced from oxaloacetate, or (c) 2HG produced from αKG in 6 hr reactions 
with either no enzyme, LDH purified from bovine heart (5 units/ml), or MDH purified from 
porcine heart (5 units/ml) in potassium phosphate buffer 33 mM, pH 7.0, with NADH 0.22 
mM and 1 mM substrate. The top panels show mixtures of standards for L- and D-lactate, 
malate, and 2HG that were derivatized and analyzed by the same method in parallel. Vertical 
blue and red bars in background serve as visual references to facilitate identification of L- 
and D- enantiomers, respectively. Results throughout figure are representative of ≥3 
independent experiments.
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Figure 3. Acidic pH enhances L-2HG production by LDH and MDH
(a, b) Increased rates of NADH consumption in acidic reaction conditions with purified (a) 
LDH or (b) MDH at 5 units/ml and αKG 3 mM. Data for a and b are mean ± 95% c.i. for 
triplicate reactions. (c, d) Reaction velocities as a function of αKG concentration for 
purified (c) LDH or (d) MDH at 5 units/ml. (e, f) Chiral LC-MS analysis of 2HG 
enantiomers from 6 hr reactions with purified (e) LDH or (f) MDH at 5 units/ml and αKG 1 
mM. (g) Reaction velocities as a function of pyruvate concentration for purified LDH at 1 
μg/ml. (h) Chiral LC-MS analysis of lactate enantiomers from 6 hr reactions with purified 
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LDH at 5 units/ml and pyruvate 1 mM. Reactions were in potassium phosphate buffer 33 
mM at indicated pH with NADH 0.22 mM. Data for c, d, and g are mean ± s.d. for triplicate 
reactions. Results throughout figure are representative of ≥3 independent experiments.
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Figure 4. LDH exhibits pH-sensitive reduction of alpha-ketoacids with carboxylate tails
(a) Relative rates of NADH consumption at indicated pH with purified LDH 5 units/ml, 
NADH 0.22 mM, and substrate 1 mM. For each substrate, the rate at pH 7.4 was normalized 
to 1 to illustrate degree of rate enhancement with acidification. Structures for substrates 
alpha-ketoglutarate (αKG), phenylpyruvate (PP), and hydroxyphenylpyruvate (HPP). (b) 
Relative rates of NADH consumption at indicated pH with purified LDH 5 units/ml, NADH 
0.22 mM, and substrate 1 mM. For each substrate, the rate at pH 7.4 was normalized to 1 to 
illustrate degree of rate enhancement with acidification. Structures for alpha-ketoacid 
substrates with carboxylate tails, oxaloacetate (OAA), αKG, oxoadipic acid (OAdA) along 
with their respective methylated counterparts alpha-ketobutyrate (αKB), oxopentanoic acid 
(OPA), and ketohexanoic acid (KHA). Data are mean ± s.d. for triplicate reactions. Results 
throughout figure are representative of ≥3 independent experiments.
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Figure 5. Acidity-induced rate enhancement arises from preference of LDHA for protonated 
form of αKG
(a) Virtually docked structure of deprotonated αKG (yellow) bound to LDHA, showing a 
potentially unfavorable interaction between the carbonyl of the Q100 residue, and the tail of 
αKG. (b) Virtually docked structure of protonated αKG (yellow) bound to LDHA, showing 
a potential hydrogen-bond interaction between the carbonyl of the Q100 residue, and the 
protonated carboxylate tail of αKG, predicted to be the dominant bound species by Monte 
Carlo simulations. (c) The equilibrium of protonation states of the tail of αKG in solution. 
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Shown on the right is the theoretical free energy penalty of protonating the tail at pH 7.4 
(ΔGpH 7.4) and pH 6.0 (ΔGpH 6.0) in units of kBT where kB is the Boltzmann constant and T 
is the absolute temperature. (d–f, g) Wildtype (WT) or mutant (Q100R) LDHA enzymes 
were purified and used in enzymatic reactions with (d) alpha-ketoglutarate (αKG), (e) 
oxaloacetate (OAA), (f) oxopentanoic acid (OPA), or (g) pyruvate (Pyr). Reactions were 
performed in potassium phosphate buffer 33 mM at the indicated pH, NADH 0.22 mM, 1 
mM substrate, and enzyme at (d, f) 7 μg/ml, (e) 0.7 μg/ml, or (g) 0.07 μg/ml. Data for d–g 
are mean ± s.d. for triplicate reactions. Results throughout figure are representative of ≥3 
independent experiments.
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Figure 6. Acid-enhanced production of L-2HG stabilizes HIF-1α
(a) SFXL cells were lysed in non-denaturing conditions at indicated pH. Cell lysates were 
incubated for 16 hr with αKG 1 mM and NADH 0.22 mM. Total 2HG was analyzed by GC-
MS. (b) Lysate reactions were prepared as in a with addition of either vehicle or oxamate 1 
mM. L-2HG was measured by chiral LC-MS. Data are mean ± s.d. for triplicate reactions. 
(c) SFXL cells were cultured for 24 hr in standard DMEM or DMEM titrated to pH 6.0 
(‘acid’) with vehicle or cell-permeable dimethyl-αKG 5 mM. Total 2HG was measured by 
GC-MS. Data are mean ± s.d. for triplicate wells. (d) Quantification of intracellular L- and 
D-2HG concentrations by LC-MS (see Online Methods). Data are mean ± s.d. of a total of 6 
replicates per condition from 2 independent experiments. (e) 293T cells were cultured for 24 
hr as in c with addition of vehicle or MG132 10 μM for the final 1 hr. Western blotting of 
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nuclear extracts shows HIF-1α, hydroxyl-HIF-1α, and Ezh2 (loading control). (f) LDHA 
and MDH2 were targeted by siRNAs in SFXL cells followed by culture for 24 hr as in c. 
Western blot for c used whole cell lysates, while e and f used nuclear extracts. Full blot 
images for c, e and f are shown in Supplementary Fig. 11. Results for a–c and e are 
representative of ≥3 independent experiments. Results for f are representative of 2 
independent experiments.
Intlekofer et al. Page 26
Nat Chem Biol. Author manuscript; available in PMC 2017 September 06.
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
